Eli Lilly and Co. announced results from the phase III BRUIN CLL-321 trial evaluating pirtobrutinib (Jaypirca), a non-covalent Bruton’s tyrosine kinase inhibitor in adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma previously treated with a covalent BTK inhibitor.
Two drug combinations, Tecvayli (teclistamab-cqyv) + Talvey (talquetamab-tgvs), a BCMA and GPRC5D dual antigen targeting regimen, and Talvey + pomalidomide (Pomalyst, sponsored by Bristol Myers Squibb), demonstrated statistically significant and clinically meaningful improvements in progression-free survival and overall survival compared with investigator’s choice standard of care for adult patients with relapsed or refractory multiple myeloma who received 1 to 4 prior lines of therapy, including an anti-CD38 antibody and lenalidomide.
